indication
Vitamin preparation for the prevention of bleeding (antihemorrhagic).
The drug is used to prevent and treat bleeding due to vitamin K deficiency in newborns.
contraindication
The drug must not be used
if your child is allergic to phytomenadione (vitamin K1) or any of the other ingredients of this medicine.
Dosage of Konakion MM 2mg
Always use this medicine exactly as described or as told to you by your doctor, pharmacist or nurse. Check with your doctor, pharmacist or nurse if you are unsure.
The following information applies unless your doctor prescribes the drug differently.
Prevention of bleeding due to vitamin K deficiency
Healthy newborns born at or near estimated due date
These newborns will receive either:
a single 1 mg injection at or shortly after birth, or
starting dose of 2 mg by mouth (by mouth) at birth or shortly after birth. This dose is followed by a second dose of 2 mg 4 to 7 days later and a third dose of 2 mg 1 month later. For exclusively formula-fed infants, the third dose may be omitted.
Newborns at particular risk of bleeding, born prematurely or at term (eg, newborns with respiratory distress syndrome at birth; newborns with inflammatory disease and/or bile and bile flow disorders [cholestatic] liver dysfunction; newborns who cannot swallow; newborns of mothers treated with drugs that reduce blood clotting [anticoagulants] or drugs to treat seizures [antiepileptic drugs])
These neonates are given Konakion MM 2 mg as an injection at or shortly after birth.
Additional injections may follow later if your child is still at risk of bleeding.
Other dosages:
Newborns who receive vitamin K by mouth (oral) drip and who are breastfed (i.e., not formula-fed) may need more than three oral doses of vitamin K.
Formula-fed newborns who received the planned two doses of vitamin K are unlikely to require additional doses of vitamin K because vitamin K is already present in the formula.
Treatment of bleeding due to vitamin K deficiency
Initial dose: 1 mg phytomenadione (equivalent to 0.1 ml solution) in term infants or 0.4 mg/kg body weight (equivalent to 0.04 ml/kg body weight) intravenously in premature infants; if necessary, additional doses depending on the clinical picture and the state of blood coagulation. If necessary, drug treatment should be accompanied by additional measures, such as transfusion of whole blood or coagulation factors, to compensate for severe blood loss and delayed response to vitamin K1.
Please talk to your doctor or pharmacist if you have the impression that the medicine is too strong or too weak.
If you use more than you should
To date, nothing is known about the consequences of an overdose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.pregnancy
information is absent
on a way
The drug is administered orally, intramuscularly or intravenously (i.e. by injection into a muscle or into a vein).
How it is given depends on what the medicine is used for and whether your baby was born prematurely.
Oral administration
A clear solution is placed directly into the child’s mouth.
parenteral administration
The drug must not be diluted or mixed with other drugs for parenteral administration.
Intravenous administration of the drug must be carried out especially slowly in order to ensure maximum dilution of the injection solution with blood flow.
Interaction with Konakion MM 2 mg
The use of the drug in conjunction with other drugs
Tell your doctor or pharmacist if you are taking/using, have recently taken/have used or might take/use any other medicines.
Like N-methylthiotetrazole cephalosporins, coumarin derivatives inhibit epoxide reductase in the vitamin K cycle and thus the function of the vitamin K 1 cofactor in the carboxylation reaction.
Acetylsalicylic acid and other salicylates also reduce the effect of vitamin K by inhibiting the carboxylase-reductase system.
Anticonvulsants, such as phenobarbital and diphenylhydantoin, and some anti-TB drugs, such as isoniazid and rifampicin, can cause bleeding due to vitamin K deficiency in newborns whose mothers took these drugs during pregnancy. The exact mechanism is still unclear.
In the case of anticoagulant treatment with coumarin derivatives, vitamin K 1 interferes with their therapeutic effect and thus causes a risk of thrombosis.
Buy Konakion
Price Konakion
Цена Конакион
Купить Конакион
Acheter Konakion
Prix Konakion
Comprar Konakion
Precio Konakion
